O-GlcNAc Modification Protects Against Protein Misfolding and Aggregation in Neurodegenerative Disease
Overview
Authors
Affiliations
Post-translational modifications (PTMs) of proteins are becoming the focus of intense research due to their implications in a broad spectrum of neurodegenerative diseases. Various PTMs have been identified to alter the toxic profiles of proteins which play critical roles in disease etiology. In Alzheimer's disease (AD), dysregulated phosphorylation is reported to promote pathogenic processing of the microtubule-associated tau protein. Among the PTMs, the enzymatic addition of N-acetyl-d-glucosamine (GlcNAc) residues to Ser/Thr residues is reported to deliver protective effects against the pathogenic processing of both amyloid precursor protein (APP) and tau. Modification of tau with as few as one single O-GlcNAc residue inhibits its toxic self-assembly. This modification also has the same effect on the assembly of the Parkinson's disease (PD) associated α-synuclein (ASyn) protein. In fact, O-GlcNAcylation ( O-linked GlcNAc modification) affects the processing of numerous proteins implicated in AD, PD, amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) in a similar manner. As such, manipulation of a protein's O-GlcNAcylation status has been proposed to offer therapeutic routes toward addressing multiple neurodegenerative pathologies. Here we review the various effects that O-GlcNAc modification, and its modulated expression, have on pathogenically significant proteins involved in neurodegenerative disease.
Chen L, Jiang H, Licinio J, Wu H Mol Psychiatry. 2025; .
PMID: 40033044 DOI: 10.1038/s41380-025-02943-z.
Characterization and chemoproteomic profiling of protein O-GlcNAcylation in SOD1-G93A mouse model.
Hao Y, Li Z, Du X, Xie Q, Li D, Lei S Mol Med. 2025; 31(1):82.
PMID: 40021952 PMC: 11871760. DOI: 10.1186/s10020-025-01134-4.
Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review.
Dunning E, Decourt B, Zawia N, Shill H, Sabbagh M Neurol Ther. 2024; 13(4):975-1013.
PMID: 38743312 PMC: 11263316. DOI: 10.1007/s40120-024-00614-9.
N-glycosylation as a eukaryotic protective mechanism against protein aggregation.
Duran-Romana R, Houben B, De Vleeschouwer M, Louros N, Wilson M, Matthijs G Sci Adv. 2024; 10(5):eadk8173.
PMID: 38295165 PMC: 10830103. DOI: 10.1126/sciadv.adk8173.
-GlcNAcylation regulates OTX2's proteostasis.
Wulff-Fuentes E, Boakye J, Kroenke K, Berendt R, Martinez-Morant C, Pereckas M iScience. 2023; 26(11):108184.
PMID: 38026167 PMC: 10661118. DOI: 10.1016/j.isci.2023.108184.